Skip to main content

Table 7 Arrangement by the tumor sites in each Group

From: Systematic assessment of HER2/neu in gynecologic neoplasms, an institutional experience

Primary Site

Group I

Group II

Group III

Group IV

Group V

CCCA

SCA

ENAdCA

MxSEAdCA

Other

 

n

HER2+

n

HER2+

n

HER2+

n

HER2+

n

HER2+

Endometrium

6

2 (33.3 %)

9

4 (44.4 %)

22

 

11

1 (9.1 %)

10

1 (10.0 %)

Ovary

5

1 (20.0 %)

30

1 (3.3 %)

5

 

13

 

3

 

Fallopian Tube

  

1

 

1

     

Peritoneum

  

5

   

1

   

Pelvic Mass

      

1

 

1

 

Cervix

        

1

 

All Sites

11

3 (27.3 %)

45

5 (11.1 %)

28

0 (0.0 %)

26

1 (3.9 %)

15

1 (6.7 %)

  1. Bold data signify the positive results
  2. CCCA clear cell carcinoma, SCA serous carcinoma, ENAdCA endometrioid adenocarcinoma, MxSEAdCA mixed surface epithelial adenocarcinoma, Other other neoplasms, HER2+ positive HER2/neu